Skip to main content
Premium Trial:

Request an Annual Quote

DxS: Sep 19, 2007

DxS this week launched its B-RAF Mutation Detection Kit, which detects V600E, the most common mutation in the B-RAF oncogene. The V600E occurs in many types of cancer, including melanoma, colorectal, and lung cancer.
“Tumors with the V600E mutation are exquisitely sensitive to drugs that inhibit the MEK pathway; therefore, this assay is likely to be useful to investigate which patients will respond to these drugs,” DxS said in a statement. Pfizer, AstraZeneca, and Roche are some companies currently developing MEK inhibitor drugs.
According to DxS, the assay can detect less than 1 percent of mutants in a background of wild type genomic DNA and has a limit of detection of 5 copies or below.

Filed under

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.